BioMarin Pharma (BMRN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
BioMarin (BMRN) PT Lifted to $87 at Jefferies Posts Q3
October 24, 2014 8:24 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and boosted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $87.00 (from $84.00) following better-than-expected product sales.
Yang commented, "Better-than-expected 3Q products sales led to ~1-3% upside revision to FY14 revenue guidance (+28-29% y/y).... More
